Entera Bio Ltd. (NASDAQ:ENTX) shares fell 1.05% in pre-market trading after the clinical-stage biotechnology company reported a larger-than-expected second-quarter loss as spending increased ahead of a pivotal trial for its oral osteoporosis treatment EB613.
The company posted a loss of $0.14 per share for the quarter, compared with the analyst estimate for a loss of $0.09 per share.
Entera’s net loss widened to $7.3 million, or $0.14 per share, for the three months ended June 30, 2026. That compared with a net loss of $2.7 million, equivalent to $0.06 per share, during the same period a year earlier.
Warrant remeasurement and R&D spending increase losses
A significant portion of the year-on-year increase in Entera Bio’s quarterly loss came from a $2.7 million non-cash fair value remeasurement associated with pre-funded warrants issued as part of an April 2026 private placement.
Research and development expenditure also increased substantially as the company prepared to move EB613 into its Phase 3 programme.
R&D expenses reached $3.2 million during the quarter, more than double the $1.5 million recorded in the corresponding period of 2025.
The higher spending reflects Entera’s preparations for the registrational development programme of EB613, its oral anabolic tablet being developed for postmenopausal women with osteoporosis.
Entera prepares EB613 for pivotal Phase 3 trial
Entera reached alignment with the U.S. Food and Drug Administration in June 2026 over the design of a 12-month registrational Phase 3 study evaluating EB613.
The company intends to begin the pivotal trial in late 2026, with topline results currently expected during the second half of 2028.
“Osteoporosis is one of the foremost underserved health issues globally, and associated fracture rates continue to rise despite existing treatments,” said Miranda Toledano, Chief Executive Officer of Entera. “We are developing EB613 to address this treatment gap.”
Progress with EB613 represents a central component of Entera’s development strategy, with the company seeking to establish an oral alternative within a treatment category that has traditionally relied heavily on injectable therapies.
$275 million financing extends expected cash runway into 2030
Entera strengthened its financial position substantially following the end of the second quarter by announcing an oversubscribed $275 million private placement led by BVF Partners L.P.
According to the company, proceeds from the financing are expected to provide sufficient funding for the EB613 Phase 3 registrational programme through the anticipated submission of a New Drug Application to the FDA.
The capital raise is also expected to extend Entera Bio’s cash runway into 2030, providing greater financial visibility as the company moves through the costly late-stage development process.
Entera reported cash and cash equivalents of $11.3 million as of June 30, 2026. On a pro forma basis incorporating the July financing, management expects available resources to fund operations into 2030.
While the wider-than-expected quarterly loss weighed modestly on Entera Bio shares in pre-market trading, investor attention is likely to remain centred on preparations for the EB613 Phase 3 trial and the company’s ability to advance the programme towards a potential regulatory submission.
Entera Bio stock price
